Feasibility study of a postoperative adjuvant chemotherapy which performs the maintenance therapy of TS-1 after CBDCA+TS-1 to the patients of pathological stage II-IIIA with completely resected non-small cell lung cancer

Feasibility study of a postoperative adjuvant chemotherapy which performs the maintenance therapy of TS-1 after CBDCA+TS-1 to the patients of pathological stage II-IIIA with completely resected non-small cell lung cancer - Escargot001

Status

Active, not recruiting

Phases

Unknown

Study type

Interventional

Source

JPRN

Registry ID

JPRN-UMIN000006351

Enrollment

Registered

2011-09-15

Start date

2011-09-01

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

non-small cell lung cancer

Interventions

After CBDCA(AUC=5, day1) +TS-1(80mg/m2, day1-14) q3-4w, 3 courses, TS-1 80mg/m2 b.i.d., day 1-14 q3w, for 6 months

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: 1) pathologically proven Non-small Cell Lung Cancer 2) pathological stage II, IIIA 3) complete resection 4) at least lobectomy 5) LN dissection (ND2a) or Elective Lymph Node Dissection 6) no prior anti cancer treatment for thoracic malignancy except for this operation 7) ECOG PS 0-1 8) more than 20 years of age, under 75 years of age 9) adequate organ function 10) within 10 weeks after surgery 11) signed informed consent

Exclusion criteria

Exclusion criteria: 1) not recovered from surgical complications 2) active infection such as bacterial infection 3) patients with interstitial pneumonaitis or pulmonary fibrosis, as determined by chest CT 4) patients with myocardial infraction within 6 months 5) patinets with uncontroled complications 6) grade 2 or greater peripheral neuropathy 7) active concomitant malignancy 8) pregnant or lactating woman 9) concomitant therapy with flucytocine 10) other conditions not suitable for this study

Design outcomes

Primary

Measure	Time frame
treatment completion rate	—

Secondary

Measure	Time frame
survival period, overall survival, recurrence form, adversed event	—

Countries

Japan

Contacts

Public ContactNobuhiko Seki

Teikyo University Oncology Division

matsutani1970@yahoo.co.jp03-3964-1231

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026